Premium
The anti‐aggregating effect of BAY 41‐2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide
Author(s) -
Roger Séverine,
BadierCommander Cécile,
Paysant Jérôme,
Cordi Alex,
Verbeuren Tony J,
Félétou Michel
Publication year - 2010
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2010.00943.x
Subject(s) - sodium nitroprusside , soluble guanylyl cyclase , nitric oxide , bay , chemistry , hydroxocobalamin , platelet , guanylate cyclase , pharmacology , prostacyclin , sildenafil , vasodilation , adenosine , medicine , biochemistry , endocrinology , civil engineering , organic chemistry , cyanocobalamin , engineering , vitamin b12
BACKGROUND AND PURPOSE The purpose of the present study was to determine whether a stimulator of soluble guanylyl cyclase, BAY 41‐2272, inhibits platelet aggregation and to clarify its interaction with nitric oxide (NO). EXPERIMENTAL APPROACH Blood was collected from anaesthetized Wistar Kyoto rats. The aggregation of washed platelets was measured and the production of cAMP and cGMP was determined. KEY RESULTS In adenosine 5′‐diphosphate (ADP)‐induced platelet aggregation, the anti‐aggregating effects of BAY 41‐2272, nitroglycerin, sodium nitroprusside and DEA‐NONOate were associated with increased levels of cGMP while that of beraprost, a prostacyclin analogue, was correlated with an increase in cAMP. 1H‐[1,2,4]oxadiazolo[4,3‐a]quinoxalin‐1‐one (ODQ) prevented the effects of BAY 41‐2272 and that of nitroglycerin and sodium nitroprusside, but only inhibited the increase in cGMP produced by of DEA‐NONOate. Hydroxocobalamin, an NO scavenger, inhibited the effects of the three NO donors and BAY 41‐2272 but did not affect those of beraprost. ADP‐induced aggregation and the effects of BAY 41‐2272 were not affected by L‐nitroarginine. A positive interaction was observed between BAY 41‐2272 and the three NO donors. BAY 41‐2272 potentiated also the anti‐aggregating effects of beraprost, and again this potentiation was inhibited by hydroxocobalamin. CONCLUSIONS AND IMPLICATIONS Inhibition of platelet aggregation by BAY 41‐2272 requires the reduced form of soluble guanylyl cyclase and the presence of NO. The positive interaction observed between BAY 41‐2272 and various NO donors is qualitatively similar whatever the mechanism involved in NO release. Furthermore, a potent synergism is observed between BAY 41‐2272 and a prostacyclin analogue, but only in the presence of NO.